893747-16-5

Basic information

• Product Name: 3-(3,4-difluorophenyl)prop-2-yn-1-ol
• Synonyms: 3-(3,4-difluorophenyl)prop-2-yn-1-ol
• CAS NO: 893747-16-5
• Molecular Formula: C₉H₆F₂O
• Molecular Weight: 168.1401464
• Mol File: 893747-16-5.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-(3,4-difluorophenyl)prop-2-yn-1-ol(CAS DataBase Reference)
• NIST Chemistry Reference: 3-(3,4-difluorophenyl)prop-2-yn-1-ol(893747-16-5)
• EPA Substance Registry System: 3-(3,4-difluorophenyl)prop-2-yn-1-ol(893747-16-5)

Safety Data

• Hazardous Substances Data: 893747-16-5(Hazardous Substances Data)

Upstream product

• 64248-58-4 1,2-difluoro-4-iodo-benzene 
• 107-19-7 propargyl alcohol 

Downstream Products

• 301185-99-9 3,4-difluorobenzenepropanol 
• 376584-18-8 3,4-difluorocinnamyl alcohol 
• 1006614-50-1 (±)-trans-2-(3,4-difluorophenyl)cyclopropanecarboxylic acid 

Relevant articles and documents

Copper-catalyzed formal transfer hydrogenation/deuteration of aryl alkynes

A copper-catalyzed reduction of alkynes to alkanes and deuterated alkanes is described under transfer hydrogenation and transfer deuteration conditions. Commercially available alcohols and silanes are used interchangeably with their deuterated analogues as the hydrogen or deuterium sources. Transfer deuteration of terminal and internal aryl alkynes occurs with high levels of deuterium incorporation. Alkyne-containing complex natural product analogues undergo transfer hydrogenation and transfer deuteration selectively, in high yield. Mechanistic experiments support the reaction occurring through a cis-alkene intermediate and demonstrate the possibility for a regioselective alkyne transfer hydrodeuteration reaction.

Synthesis method of anticoagulant drug Ticagrelor raw material intermediate

The invention relates to a synthesis method of an anticoagulant drug Ticagrelor raw material intermediate. The method comprises the following steps: (a) adding toluene into a reaction vessel, carryingout replacement by using N2 for a plurality of times, a

Novel 5-(3-aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-diones as antihyperglycemic agents

Novel 5-(3-aryl-2-propynyl)-5-(arylsulfonyl)thiazolidine-2,4-diones and 5-(3-aryl-2-propynyl)5-(arylsulfanyl)thiazolidine-2,4-diones were prepared and evaluated as oral antihyperglycemic agents in the obese, insulin resistant db/db mouse model at 100 mg/kg and, if the analogue had sufficient potency, 20 mg/kg. The sulfonylthiazolidinediones, 2, were more potent than the corresponding sulfanylthiazolidinedione congeners, 1. With regard to substituent effects on the 3-propynyl phenyl ring (Ar') of 2, 4-halogen substitution generally resulted in the more potent analogues. Substituent effects on the phenylsulfonyl moiety (Ar) of 2 were less clear, although para-halogen substitution on Ar generally was preferable. 2-Pyridinesulfonyl derivatives (Ar = 2-pyridine in 2) also had good potency. Several compounds from series 2 were effective at lowering glucose and insulin in the obese, insulin resistant ob/ob mouse at the 50 mg/kg oral dose. Compound 20 significantly improved the glucose tolerance of obese, insulin resistant Zucker rats at the 20 mg/kg dose level and had no effect on plasma glucose or on glucose tolerance in normal rats fasted for 18 h at the 100 mg/kg level.